Everything about Chronic Granulomatous Disease totally explained
Chronic granulomatous disease (CGD) is a diverse group of
hereditary diseases in which certain cells of the
immune system have difficulty forming the reactive
oxygen compounds (most importantly, the
superoxide radical) used to kill certain ingested
pathogens. This leads to the formation of
granulomata in many organs. CGD affects about 1 in 200,000 people in the
United States, with at least 20 new cases diagnosed each year.
This condition was first described in 1957 as "a fatal granulomatosus of childhood". The underlying cellular mechanism that causes chronic granulomatous disease was discovered in 1967, and research since that time has further elucidated the molecular mechanisms underlying the disease.
Pathophysiology
Phagocytes (for example,
neutrophils,
monocytes, and
macrophages) require an
enzyme to produce
reactive oxygen species to destroy
bacteria after they ingest the bacteria in a process called
phagocytosis. This enzyme is termed "phagocyte NADPH oxidase" (
PHOX). The initial step in this process involves the one-electron reduction of molecular oxygen to produce
Superoxide free radical. Superoxide then undergoes a further series of reactions to produce products such as peroxide, hydroxyl radical and hypochlorite. The
reactive oxygen species this enzyme produces are toxic to bacteria and help the phagocyte kill them once they're ingested. Defects in one of the four essential subunits of this enzyme can all cause CGD of varying severity, dependent on the defect. There are over 410 known possible defects in the PHOX enzyme complex that can lead to chronic granulomatous disease The affected gene on the X chromosome codes for the gp91
protein p91-PHOX (
p is the weight of the protein in
kDa; the
g means
glycoprotein). CGD can also be transmitted in an
autosomal recessive fashion and affects other PHOX proteins. The type of mutation that causes both types of CGD are varied and may be deletions, frame-shift, nonsense, and missense.
A low level of NADPH, the cofactor required for superoxide synthesis, can lead to CGD. This has been reported in women who are
homozygous for the genetic defect causing
glucose-6-phosphate dehydrogenase deficiency (G6PD), which is characterised by reduced NADPH levels.
Clinical manifestations
Classically, patients with chronic granulomatous disease will suffer from recurrent bouts of infection due to the decreased capacity of their immune system to fight off disease-causing organisms. The recurrent infections they acquire are specific and are, in decreasing order of frequency:
People with CGD are sometimes infected with unique organisms that usually don't cause disease in people with normal immune systems. Some of the organisms that cause disease in CGD patients are
Staphylococcus aureus,
Escheria coli,
Klebsiella species,
Aspergillus species, and
Candida species.
Aspergillus has a unique propensity to cause infection in people with CGD. Of the Aspergillus species,
Aspergillus fumigatus seems to be the one that most commonly causes disease.
Most people with CGD are diagnosed in childhood, usually before age 5. Early diagnosis is important since these people can be placed on antibiotics to ward off infections before they occur.
Laboratory findings
The
nitroblue-tetrazolium (NBT) test is the original and most widely-known test for chronic granulomatous disease. It is negative in CGD, and positive in normal individuals. This test depends upon the direct reduction of NBT by
superoxide free radical to form an insoluble formazan. This test is simple to perform and gives rapid results, but only tells whether or not there's a problem with the PHOX enzymes, not how much they're affected. An advanced test called the cytochrome C reduction assay tells physicians how much superoxide a patient's phagocytes can produce. Once the diagnosis of CGD is established, a genetic analysis may be used to determine exactly which mutation is the underlying cause.
Treatment
Management of chronic granulomatous disease revolves around two goals: 1) diagnose the disease early so that
antibiotics can be given to keep an infection from occurring, and 2) educate the patient about his or her condition so that prompt treatment can be given if an infection occurs.
Physicians often prescribe the antibiotic
trimethoprim-sulfamethoxazole to prevent bacterial infections. This drug also has the benefit of sparing the normal bacteria of the digestive tract. Fungal infection is commonly prevented with
itraconazole, although a newer drug of the same type called
voriconazole may be more effective. The use of this drug for this purpose is still under scientific investigation.
Interferon, in the form of
interferon gamma-1b (Actimmune) is approved by the
Food and Drug Administration for the prevention of infection in CGD. It has been shown to prevent infections in CGD patients by 70% and to reduce their severity. Although its exact mechanism is still not entirely understood, it has the ability to give CGD patients more immune function and therefore, greater ability to fight off infections. This therapy has been standard treatment for CGD for several years.
Gene therapy is currently being studied as a possible treatment for chronic granulomatous disease. CGD is well-suited for gene therapy since it's caused by a mutation in single gene which only affects one body system (the
hematopoietic system). Viruses have been used to deliver a normal gp91 gene to rats with a mutation in this gene, and subsequently the phagocytes in these rats were able to produce
oxygen radicals.
In 2006, two human patients with X-linked chronic granulomatous disease underwent gene therapy and blood cell precursor
stem cell transplantation to their
bone marrow. Both patients recovered from their CGD, clearing pre-existing infections and demonstrating increased oxidase activity in their neutrophils. However, long-term complications of this therapy are unknown.
Prognosis
The prognosis of chronic granulomatous disease is guarded, with long-term outcomes closely tied to early diagnosis and early therapeutic intervention. With increasing treatment options for CGD the life-span for these patients is expected to also increase.
Further Information
Get more info on 'Chronic Granulomatous Disease'.
|
External Link Exchanges
Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:
<a href="http://chronic_granulomatous_disease.totallyexplained.com">Chronic granulomatous disease Totally Explained</a>
Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned. |
